Targeting PD‐L1 with DNA Aptamers and Conjugated with Gemcitabine as a Novel Therapeutic Strategy for Bladder Cancer Chemotherapy Combined with Immunotherapy

Cancer Therapy Aptamers have great functions in carrier drug delivery and have broad application prospects in the field of biomedicine. In article number 2300104, Jianye Liu and co-workers report the synthesis of a novel material, PD-L1-GEMs wherein the PD-L1 aptamer and gemcitabine, which has targeting ability, are coupled. The PD-L1-GEMs facilitate targeted chemotherapy and immunotherapy for bladder cancer simultaneously, greatly enhancing the efficacy of gemcitabine and reducing its side effects.